
The review highlights the limited effectiveness of current treatments for Coronary Microvascular Dysfunction (CMD). Despite a thorough evaluation of 14 studies covering 9 treatments, only quinapril and ranolazine showed improvements in coronary flow reserve (CFR) and angina. However, the overall evidence quality remains low, underscoring the need for better clinical trials in this area.
Like
Save
Share